Carmat Heart Sale in 2-5 Years, CEO Tells France Info

Carmat SAS, whose artificial heart was implanted in a patient for the first time last month, sees the commercialization of the device in “two-to-five years,” Chairman Jean-Claude Cadudal said in an interview on France Info Radio.

The patient who got the implant on Dec. 18 is “doing as well as is possible,” after an operation “of such gravity,” Cadudal told the radio station.

Three more such implants are planned in France, the executive said.

He said the four implants would be the basis for seeking certification for the device in Europe to allow it to be sold commercially. The company would need similar approvals in the U.S., he said.

(Corrects Cadudal’s title in first paragraph in story published yesterday.)
Before it's here, it's on the Bloomberg Terminal.
LEARN MORE